In 2001 the introduction of Imatinib Mesylate (IM), a semi-specific BCR-ABL1 tyrosine kinase inhibitor, improved the outcome of CML patients in chronic phase, generating unprecedented rates of hematologic, cytogenetic and molecular response [8–10]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.